| Wayne V Arnold, DO | |
|
2 Bala Plz Ste Pl20, Bala Cynwyd, PA 19004-1501 | |
| (610) 660-0800 | |
| (610) 660-0360 |
| Full Name | Wayne V Arnold |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 44 Years |
| Location | 2 Bala Plz Ste Pl20, Bala Cynwyd, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346252186 | NPI | - | NPPES |
| 0009298300003 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | OS004637L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Eleanor's Garden Llc | Phila, PA | Hospice |
| Main Line Health Homecare & Hospice - Hospice | Radnor, PA | Hospice |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Metro Physicians Specialty Group, P.c. | 2860466794 | 3 |
News Archive
For patients managing cancer and other chronic health issues, painkillers such as morphine and Vicodin are often essential for pain relief. The body's natural tendency to develop tolerance to these medications, however, often requires patients to take higher doses - increasing risks of harmful side effects and dependency.
GNC has announced the introduction of its latest immune health product, ViraBLOC. ViraBLOC is a clinically tested immune defense product based on patent-pending elderberry extract from HerbalScience Group and is now available nationwide through GNC.
A course of injections in childhood might help protect people from heart disease later in life. And for those whose arteries are already clogged up, a dose of antibodies could provide immediate benefits. That's the enticing vision raised by animal studies.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.
Contact tracing data from a new preprint study on the medRxiv* preprint server provides further evidence that the B.1.1.7 variant — first reported in the United Kingdom — has a high transmission rate. The research, led by Birgitte Freiseleben de Blasio from the Norwegian Institute of Public Health and the University of Oslo in Norway, estimates B.1.1.7 has a 60% greater transmission within households than other severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.
› Verified 4 days ago
| Entity Name | Primary Homecare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629023593 PECOS PAC ID: 3274437462 Enrollment ID: O20031120000241 |
News Archive
For patients managing cancer and other chronic health issues, painkillers such as morphine and Vicodin are often essential for pain relief. The body's natural tendency to develop tolerance to these medications, however, often requires patients to take higher doses - increasing risks of harmful side effects and dependency.
GNC has announced the introduction of its latest immune health product, ViraBLOC. ViraBLOC is a clinically tested immune defense product based on patent-pending elderberry extract from HerbalScience Group and is now available nationwide through GNC.
A course of injections in childhood might help protect people from heart disease later in life. And for those whose arteries are already clogged up, a dose of antibodies could provide immediate benefits. That's the enticing vision raised by animal studies.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.
Contact tracing data from a new preprint study on the medRxiv* preprint server provides further evidence that the B.1.1.7 variant — first reported in the United Kingdom — has a high transmission rate. The research, led by Birgitte Freiseleben de Blasio from the Norwegian Institute of Public Health and the University of Oslo in Norway, estimates B.1.1.7 has a 60% greater transmission within households than other severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.
› Verified 4 days ago
| Entity Name | Metro Physicians Specialty Group, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568407757 PECOS PAC ID: 2860466794 Enrollment ID: O20040825000620 |
News Archive
For patients managing cancer and other chronic health issues, painkillers such as morphine and Vicodin are often essential for pain relief. The body's natural tendency to develop tolerance to these medications, however, often requires patients to take higher doses - increasing risks of harmful side effects and dependency.
GNC has announced the introduction of its latest immune health product, ViraBLOC. ViraBLOC is a clinically tested immune defense product based on patent-pending elderberry extract from HerbalScience Group and is now available nationwide through GNC.
A course of injections in childhood might help protect people from heart disease later in life. And for those whose arteries are already clogged up, a dose of antibodies could provide immediate benefits. That's the enticing vision raised by animal studies.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.
Contact tracing data from a new preprint study on the medRxiv* preprint server provides further evidence that the B.1.1.7 variant — first reported in the United Kingdom — has a high transmission rate. The research, led by Birgitte Freiseleben de Blasio from the Norwegian Institute of Public Health and the University of Oslo in Norway, estimates B.1.1.7 has a 60% greater transmission within households than other severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.
› Verified 4 days ago
| Entity Name | At Home Cardiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972201549 PECOS PAC ID: 8022478809 Enrollment ID: O20230712003733 |
News Archive
For patients managing cancer and other chronic health issues, painkillers such as morphine and Vicodin are often essential for pain relief. The body's natural tendency to develop tolerance to these medications, however, often requires patients to take higher doses - increasing risks of harmful side effects and dependency.
GNC has announced the introduction of its latest immune health product, ViraBLOC. ViraBLOC is a clinically tested immune defense product based on patent-pending elderberry extract from HerbalScience Group and is now available nationwide through GNC.
A course of injections in childhood might help protect people from heart disease later in life. And for those whose arteries are already clogged up, a dose of antibodies could provide immediate benefits. That's the enticing vision raised by animal studies.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.
Contact tracing data from a new preprint study on the medRxiv* preprint server provides further evidence that the B.1.1.7 variant — first reported in the United Kingdom — has a high transmission rate. The research, led by Birgitte Freiseleben de Blasio from the Norwegian Institute of Public Health and the University of Oslo in Norway, estimates B.1.1.7 has a 60% greater transmission within households than other severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Wayne V Arnold, DO Po Box 14, Bala Cynwyd, PA 19004-9998 Ph: (610) 660-0800 | Wayne V Arnold, DO 2 Bala Plz Ste Pl20, Bala Cynwyd, PA 19004-1501 Ph: (610) 660-0800 |
News Archive
For patients managing cancer and other chronic health issues, painkillers such as morphine and Vicodin are often essential for pain relief. The body's natural tendency to develop tolerance to these medications, however, often requires patients to take higher doses - increasing risks of harmful side effects and dependency.
GNC has announced the introduction of its latest immune health product, ViraBLOC. ViraBLOC is a clinically tested immune defense product based on patent-pending elderberry extract from HerbalScience Group and is now available nationwide through GNC.
A course of injections in childhood might help protect people from heart disease later in life. And for those whose arteries are already clogged up, a dose of antibodies could provide immediate benefits. That's the enticing vision raised by animal studies.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.
Contact tracing data from a new preprint study on the medRxiv* preprint server provides further evidence that the B.1.1.7 variant — first reported in the United Kingdom — has a high transmission rate. The research, led by Birgitte Freiseleben de Blasio from the Norwegian Institute of Public Health and the University of Oslo in Norway, estimates B.1.1.7 has a 60% greater transmission within households than other severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.
› Verified 4 days ago
Marjorie Friedman, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 225 E City Ave Ste 109, Bala Cynwyd, PA 19004 Phone: 215-503-3838 | |
Dr. Jonathan L. Gelfand, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 205 Rhyle Ln, Bala Cynwyd, PA 19004 Phone: 215-805-5413 Fax: 610-672-9532 | |
Timothy A Woods, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 333 E City Ave, Suite Il -40, Bala Cynwyd, PA 19004 Phone: 610-664-1977 Fax: 610-667-6052 | |
Daniel H. Parish, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 50 Monument Road, Third Floor Suite 301, Bala Cynwyd, PA 19004 Phone: 610-668-2570 Fax: 610-668-2808 | |
Dr. Robert Weiss, M D Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: Total Access Medical, 191 Presidential Blvd C135, Bala Cynwyd, PA 19004 Phone: 610-667-7203 Fax: 610-667-0447 | |
Alexandra Marie Ristow, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 150 Monument Rd Ste 500, Bala Cynwyd, PA 19004 Phone: 855-478-8208 | |
Dr. Mary Van Den Berg-wolf, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 225 E City Ave, Suite 109, Bala Cynwyd, PA 19004 Phone: 215-503-3838 |